FDAnews
www.fdanews.com/articles/197396-bergenbio-doses-first-covid-19-patient-with-bemcentinib-in-accord-trial
BerGenBio Doses First COVID-19 Patient with Bemcentinib in ACCORD Trial

BerGenBio Doses First COVID-19 Patient with Bemcentinib in ACCORD Trial

June 3, 2020

BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment.

The study will assess the oral kinase inhibitor in addition to standard of care. It will recruit 120 hospitalized COVID-19 patients, giving 60 participants bemcentinib in addition to the standard of care, while the others will receive only the standard of care.

Bemcentinib is the first candidate to be tested as a part of the UK’s Accelerating COVID-19 Research & Development (ACCORD) platform trial of multiple early-stage COVID-19 treatments.

View today's stories